• Member News

Touchlight Genetics Press Release: World leading DNA technology is expanding its operations in London as it grows to meet global DNA demand.

Touchlight Genetics Ltd has developed a revolutionary DNA technology that can synthetically manufacture commercial scale DNA in a two-week process – a technology that is disrupting the decades old fermentation approach. The process uses two enzymes, and basic benchtop laboratory equipment to produce DNA of any sequence for therapeutic applications.

PureTech Health Notes US Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech

PureTech Health plc, an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal biomarkers programme. The patent broadly covers methods of assessing a mental or physical condition of a subject, using phonetic structures, or phones, extracted from speech audio waveforms. The issued patent is exclusively licensed under an agreement with the Massachusetts Institute of Technology (MIT) and provides coverage through at least 2032.

Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD

Zug, Switzerland – September 20, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and its partner in Japan, Shionogi & Co., Ltd, announced that a Phase 3 study evaluating INTUNIV® (guanfacine hydrochloride prolonged release) in adult patients with attention deficit hyperactivity disorder (ADHD) in Japan has positive topline results, and the study met the primary endpoint. This is the first clinical trial evaluating INTUNIV in adult patients (18 years old and over) with ADHD.

Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

Cambridge and Newcastle, UK, 20th September, 2017: Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development Company, and IONTAS Limited (IONTAS), a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today announced a collaboration for the development of ADCs for difficult-to-treat cancers. As part of the agreement, IONTAS will generate novel, fully human antibodies against specified targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink® and its in-house portfolio of novel toxins.

Synpromics announces gene therapy research partnership with Solid Biosciences

Edinburgh, UK, 20th September 2017 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).

Synthace raises £7.3m to accelerate biotechnology to enable faster breakthroughs

Synthace Ltd., the technology company behind the Antha operating system for biology today announced that it has raised £7.3m ($9.6m) in Series A funding.

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second orally-active small molecule cancer therapeutic agent to enter clinical trials during the past 12 months.

Diurnal Group publish pivotal phase 3 data for Infacort in Clinical Endocrinology

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that data from the pivotal Phase III trial for its lead product Infacort® are published in Clinical Endocrinology.

Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress

Lexington, MA – September 15, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) will share new Attention Deficit Hyperactivity Disorder (ADHD) research at the upcoming Psych Congress in New Orleans, Louisiana from September 16-19, 2017.

Scancell - Final Results for the year ended 30 April 2017

Landmark five year survival achieved in resected SCIB1 patients Emerging pipeline of three products across five cancer indications